• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Meeting, 2007 Presentations

Issues and Controversies in DILI
(DILI = drug-induced liver injury)


Session I: FDA Concept Paper: Premarketing Evaluation of DILI (Moderator – Paul Watkins, M.D., UNC, DILIN)

How can we best find and study DILI in clinical trials?

Session II: Does Preexisting Liver Disease Make DILI More Likely? (Moderator – Neil Kaplowitz, M.D., USC)

Does liver disease increase chances of getting DILI?

Session III: Role of the Immune System in DILI, (Moderator – Holly A. Read, M.D., Abbott)

Why the variable latent period between exposure and onset of DILI?


Contact list for Authors.